My COVID-19 Recovery Took Weeks, but I’m Staying Positive

There I was, just living each day and minding my own business. I was following all the guidelines from the U.S. Centers for Disease Control and Prevention and wearing a mask everywhere I went, when all of a sudden, BAM! The COVID-19 virus found me. What followed were…

Albrioza, an oral therapy for amyotrophic lateral sclerosis (ALS) still widely known as AMX0035, is now commercially available in Canada, its developer, Amylyx Pharmaceuticals, announced. Its market availability comes about 1.5 months after the therapy was conditionally approved by Health Canada for this neurodegenerative disease. The regulatory decision was based on…

TDP-43 protein abnormalities characteristic of most amyotrophic lateral sclerosis (ALS) cases contribute to the loss of motor neurons mostly by limiting the function of a protein called stathmin-2 (STMN2), a study reported. Results indicate that boosting STMN2 levels may be a useful approach in treating ALS, according to its…

Pasithea Therapeutics has gained access to AU$1 million (about $694,000) to further its research into anti-integrin antibodies as potential treatments for amyotrophic lateral sclerosis (ALS). The non-dilutive funds became available following the company’s acquisition of Alpha-5 Integrin, the preclinical biotech company that originally developed the experimental antibodies for…

Music had been a source of connection and mild contention early in my relationship with my husband, Todd, but it hadn’t been much of either since Todd became paralyzed due to ALS. Our first date was to an Alison Krauss & Union Station concert. Todd was new to Milwaukee…

Amylyx Pharmaceuticals has partnered with Sunnybrook Research Institute (SRI) to find new therapeutic candidates for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Under terms of the two-year sponsored research agreement, SRI will work to identify potential therapeutics that potently and specifically inhibit Bax and Bak, two proteins…

The U.S. Food and Drug Administration (FDA) has agreed to review an application from Biogen for approval of the company’s experimental therapy tofersen to treat amyotrophic lateral sclerosis (ALS) associated with mutations in the SOD1 gene. The FDA has granted the application accelerated review and a decision…

The National Institutes of Health (NIH) has awarded $2.3 million to advance into testing an app that could improve how amyotrophic lateral sclerosis (ALS) is diagnosed, track the disease’s progression, and help assess a treatment’s effectiveness. The three-year Small Business Technology Transfer (STTR) grant was awarded to Modality.AI and…

Tara Gottlieb lost her father to amyotrophic lateral sclerosis (ALS) in November, but the Massachusetts resident said she’s only just begun advocating for people with the disease and working to help find a cure. Gottlieb remembers her father, David Gottlieb, as a generous, selfless, caring man. She and her brother,…

Orphan drug status has been recommended in the EU for Clene Nanomedicine’s CNM-Au8, an oral therapy candidate for amyotrophic lateral sclerosis (ALS), by a committee of the European Medicines Agency (EMA). CNM-Au8 is emerging as a promising treatment for the progressive neurodegenerative condition, with…